Regeneron weight-loss drug halves muscle loss with Novo's semaglutide
Regeneron’s experimental anti-myostatin drug trevogrumab combined with Novo Nordisk’s semaglutide cut muscle loss by 50% in an obesity trial, with 75 mg preserving over 70% of lean mass at 52 weeks
Reuters3 min read
Share

(i yunmai on Unsplash)
Add Emirates 24|7 to your Google News
Text Size:
